Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition
CSL Behring to Acquire Biotech Company Vitaeris
Details : With this acquisition, clazakizumab joins CSL842 and CSL964 as part of CSL Behring’s portfolio of products in late-stage development to address significant unmet needs in the transplant community.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
August 06, 2020
Lead Product(s) : Clazakizumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : CSL
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ciclesonide
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 24, 2014
Lead Product(s) : Ciclesonide
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifaximin
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Salix Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 15, 2014
Lead Product(s) : Rifaximin
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Salix Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rifaximin
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Salix Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
September 15, 2014
Lead Product(s) : Rifaximin
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Salix Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
August 05, 2014
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brodalumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
January 08, 2014
Lead Product(s) : Brodalumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Brodalumab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Efficacy and Safety of Brodalumab in Subjects With Psoriatic Arthritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 31, 2013
Lead Product(s) : Brodalumab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 27, 2013
Lead Product(s) : Loteprednol Etabonate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Voclosporin
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy Study of Voclosporin and Tacrolimus in Transplantation
Details : Undisclosed
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Inapplicable
April 27, 2012
Lead Product(s) : Voclosporin
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Budesonide
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
February 14, 2012
Lead Product(s) : Budesonide
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable